Mayo Clinic Proceedings Home

Famotidine Against SARS-CoV2: A Hope or Hype?

      Coronavirus disease 2019 (COVID-19) is globe-trotting, and thousands of researchers and stakeholders are spending repose-less days and sleepless nights in search of effective therapies. Currently, the entire research sphere is dealing with a pandemic triad: hypes, hypotheses, and hopes. In the absence of a specific antiviral agent or vaccine against novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), “repurposing” of old time-tested medications is being tried. Famotidine is the most recent addition to this trend, creating a lot of hustle among the public and stirring criticism in the scientific arena.
      • Borrell B.
      New York clinical trial quietly tests heartburn remedy against coronavirus. Science.
      A phase 3 trial “Multi-site Adaptive Trials Using Hydroxychloroquine for COVID-19” (MATCH; identifier: NCT04370262) has already been launched inconspicuously.
      • Borrell B.
      New York clinical trial quietly tests heartburn remedy against coronavirus. Science.
      Multi-site Adaptive Trials Using Hydroxychloroquine for COVID-19 (MATCH). website.
      This randomized double-blind clinical trial (N=1170) has been designed to compare clinical outcomes between 2 arms: one receiving hydroxychloroquine 200 mg plus famotidine (360 mg/d intravenously) and the other receiving hydroxychloroquine plus placebo. Famotidine will be administered for a maximum of 14 days or up to hospital discharge, whichever will come earlier.
      Multi-site Adaptive Trials Using Hydroxychloroquine for COVID-19 (MATCH). website.
      In this briefing, we will try to enlighten some facts regarding whether it is truly possible for famotidine to have a beneficial effect in COVID-19 or is it just hitting the castle in a Don Quixote way.
      To read this article in full you will need to make a payment


      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Borrell B.
        New York clinical trial quietly tests heartburn remedy against coronavirus. Science.
        (Published April 26, 2020)
      1. Multi-site Adaptive Trials Using Hydroxychloroquine for COVID-19 (MATCH). website.
        • Mehta P.
        • McAuley D.F.
        • Brown M.
        • Sanchez E.
        • Tattersall R.S.
        • Manson J.J.
        • HLH Across Speciality Collaboration, UK
        COVID-19: consider cytokine storm syndromes and immunosuppression.
        Lancet. 2020; 395: 1033-1034
        • Hahm K.B.
        • Kim W.H.
        • Lee S.I.
        • Kang J.K.
        • Park I.S.
        Comparison of immunomodulative effects of the histamine-2 receptor antagonists cimetidine, ranitidine, and famotidine on peripheral blood mononuclear cells in gastric cancer patients.
        Scand J Gastroenterol. 1995; 30: 265-271
        • Frei R.
        • Ferstl R.
        • Konieczna P.
        • et al.
        Histamine receptor 2 modifies dendritic cell responses to microbial ligands.
        J Allergy Clin Immunol. 2013; 132: 194-204
        • Jafarzadeh A.
        • Nemati M.
        • Khorramdelazad H.
        • Hassan Z.M.
        Immunomodulatory properties of cimetidine: Its therapeutic potentials for treatment of immune-related diseases.
        Int Immunopharmacol. 2019; 70: 156-166
        • Smolinska S.
        • Groeger D.
        • Perez N.R.
        • et al.
        Histamine receptor 2 is required to suppress innate immune responses to bacterial ligands in patients with inflammatory bowel disease.
        Inflamm Bowel Dis. 2016; 22: 1575-1586
        • Takagaki K.
        • Osawa S.
        • Horio Y.
        • et al.
        Cytokine responses of intraepithelial lymphocytes are regulated by histamine H(2) receptor.
        J Gastroenterol. 2009; 44: 285-296
        • Morichika T.
        • Takahashi H.K.
        • Iwagaki H.
        • et al.
        Histamine inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production in an intercellular adhesion molecule-1- and B7.1-dependent manner.
        J Pharmacol Exp Ther. 2003; 304: 624-633
        • Bourinbaiar A.S.
        • Fruhstorfer E.C.
        The effect of histamine type 2 receptor antagonists on human immunodeficiency virus (HIV) replication: identification of a new class of antiviral agents.
        Life Sci. 1996; 59: PL365-PL370
        • Bartlett J.A.
        • Berry P.S.
        • Bockman K.W.
        • et al.
        A placebo-controlled trial of ranitidine in patients with early human immunodeficiency virus infection.
        J Infect Dis. 1998; 177: 231-234
        • Gooptu C.
        • Higgins C.R.
        • James M.P.
        Treatment of viral warts with cimetidine: an open-label study.
        Clin Exp Dermatol. 2000; 25: 183-185
        • Kürkçüoğlu N.
        • Alli N.
        Cimetidine prevents recurrent erythema multiforme major resulting from herpes simplex virus infection.
        J Am Acad Dermatol. 1989; 21: 814-815
        • Goldstein J.A.
        Cimetidine, ranitidine, and Epstein-Barr virus infection.
        Ann Intern Med. 1986; 105: 139
        • Xie X.
        • Geng S.
        • Liu H.
        • Li C.
        • Yang Y.
        • Wang B.
        Cimetidine synergizes with praziquantel to enhance the immune response of HBV DNA vaccine via activating cytotoxic CD8(+) T cell.
        Hum Vaccin Immunother. 2014; 10: 1688-1699
        • Yang N.
        • Tanner J.A.
        • Zheng B.J.
        • et al.
        Bismuth complexes inhibit the SARS coronavirus.
        Angew Chem Int Ed Engl. 2007; 46: 6464-6468
        • Wang X.
        • Boffito M.
        • Zhang J.
        • et al.
        Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients.
        AIDS Patient Care STDS. 2011; 25: 509-515
        • Eom C.S.
        • Jeon C.Y.
        • Lim J.W.
        • Cho E.G.
        • Park S.M.
        • Lee K.S.
        Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis.
        CMAJ. 2011; 183: 310-319
        • Schoenwald P.K.
        • Sprung J.
        • Abdelmalak B.
        • Mraović B.
        • Tetzlaff J.E.
        • Gurm H.S.
        Complete atrioventricular block and cardiac arrest following intravenous famotidine administration.
        Anesthesiology. 1999; 90: 623-626

      Linked Article

      • Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis
        Mayo Clinic ProceedingsVol. 96Issue 5
        • Preview
          The article by Ghosh et al,1 in which they discuss the potential of famotidine to regulate innate and adaptive immune responses, provides a rationale to repurpose famotidine for the treatment of coronavirus disease 2019 (COVID-19). There have been few studies evaluating the use of famotidine in patients with COVID-19, and thus we performed a meta-analysis to summarize the overall effect of famotidine on the clinical outcomes in this patient population.
        • Full-Text
        • PDF
      • In Reply–Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis
        Mayo Clinic ProceedingsVol. 96Issue 5
        • Preview
          Kow and colleagues' interest in our recent letter to the editor1 regarding the potential for famotidine in COVID-19 infection was much appreciated. Obviously, their meta-analysis is small and probably not adequately powered but still suggested 37% and 7% reductions in severe disease in the general and adjusted analyses, respectively: obviously, with wide confidence intervals that were not close to statistical significance. A large-scale randomized study that was adequately powered, preferably with famotidine, started early in COVID-19, would be required to fully determine the full potential of the benefits of famotidine in COVID-19; this type of study is likely not coming in this pandemic.
        • Full-Text
        • PDF